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Purpose: To report the anatomic and functional outcome of intravitreal dobesilate to treat recurrent central serous
chorioretinopathy (CSC).
Methods: This is an interventional case report in which dobesilate was intravitreally injected in a case of recurrent
CSC. Main measures included fundoscopy, Snellen visual acuity (VA) testing, fluorescein angiography and optical
coherence tomography (OCT).
Results: We present anatomical and functional evidences, obtained as early as eleven days after the treatment, of
the efficacy of intravitreal dobesilate, in the treatment of chronic CSC condition. The effect after intravitreal
dobesilate injection for CSC might be related to the normalization of retinal architecture.
Conclusions: Intravitreal dobesilate may be an effective treatment option for recurrent CSC.
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Central serous chorioretinopathy (CSC) is a well-
characterized self-limiting disorder leading to serous neu-
rosensory elevation of the retina. The acute form of the
disease in many patients resolves spontaneously, with re-
sidual subjective impairment mainly in the form of faint
scotomas or metamorphopsia [1]. Those patients who do
not resolve spontaneously can develop chronic CSC with
retinal pigment epithelium (RPE) and photoreceptor dam-
age, resulting in permanent visual impairment.
The pathophysiology of CSC remains poorly under-
stood. However, the cascade of events leading to neuro-
sensory detachment includes, and may in fact begin with
changes in choroidal permeability [2]. We recently
reported that dobesilate, a well-characterized fibroblast
growth factor (FGF) inhibitor [3] abolished vascular
endothelial growth factor (VEGF)-driven vascular hyper-
permeability and fluid leakage [4].
CSC was first described by von Graefe in 1866. CSC is
a condition commonly seen in young or middle age adults
as a localized detachment of the neurosensory retina in
the macular region [5,6]. In acute CSC with focal leakage,* Correspondence: pedro.cuevas@hrc.es
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reproduction in any medium, provided the orRPE increases its function to absorb the subretinal fluid
and the disease is self limiting. However, in those cases
with persistent focal or chronic diffuse leakage, RPE may
decompensate and thus gradually lead to a less favourable
prognosis with visual loss [7]. Chronic CSC involves RPE
detachment, macular pigmentary change, gravitational
tract, teleangiectatic change of retinal capillaries, capillary
nonperfusion, subretinal fibrosis, neuroretinal degener-
ation, and secondary choroidal neovascularization (CNV)
[8,9]. CSC has a favourable natural course and typically
results in spontaneous resolution of the detachment and
improvement of visual function [10-12]. The high spon-
taneous remission rate favors conservative management
as a first line therapeutic option. However, in some cases
of CSC, patients may develop progressive visual loss
resulting from persistent serous retinal detachment,
cystoid macular degeneration or retinal pigment epithe-
lium decompensation [6,11]. Thus, active intervention
should be considered in CSC with a symptom duration
lasting longer than 3 months [13,14] as it occurred with
the eye included in the current study. Traditionally, the
major treatment option for persistent CSC has included
thermal laser photocoagulation [15,16]. However, focal
laser treatment is not suitable for CSC with a subfoveal
or juxtafoveal leaking point, and furthermore, possible
complications of laser photocoagulation include CNV,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ent foveal damage [17,18]. With the advent of indocya-
nine green angiography, it has been demonstrated that
CSC primarily affects the choroidal circulation and causes
multifocal areas of choroidal vascular permeability [8].
On the basis of indocyanine green angiographic findings,
photodynamic therapy (PDT) with verteporfin has also
been adapted for treatment of CSC [19]. However, photo-
dynamic therapy can be associated with inflammation, fi-
brosis and subsequently with CNV [20,21] and is not
specific enough in tackling the fundamental choroidal
problem.
The endothelial cell barrier function is regulated by
vascular endothelial tight junction proteins that are
involved in the regulation of the movement of macro-
molecules through the endothelium. Modification of
tight junction proteins by an increased concentration
of VEGF directly results in elevated permeability and,
as consequence, in tissue edema, in several patho-
logical conditions, including cancer and neovascular
diseases of the eye [22-24]. Inhibition of angiogenesis
and vascular permeability can be an effective treat-
ment for a variety of angiogenesis-dependent ocular
diseases. Accordingly, it was proposed that VEGF anti-
bodies could reduce choroidal hyperpermeability asso-
ciated with CSC.
Treatment of acute and chronic forms of CSC with
intravitreal injections of bevacizumab (Avastin) [25-28],
a monoclonal antibody against VEGF, has, nevertheless,
quite variable outcomes. Furthermore, frequent injec-
tions are normally required to achieve a final clinical
stabilization [29]. Later on, several recent findings have
additionally damped the initial enthusiasm for anti-
VEGF treatment in ocular angiogenesis-dependent dis-
eases, mainly in diabetic and age related macular cases.
Although initially side-effects of anti-VEGF medications
(endophthalmitis, rhegmatous retinal detachment, ret-
inal tear, uveitis and vitreous hemorrhage) were sup-
posed to be procedure- rather than medication-related,
the large number of available data at this moment of the
results of anti-VEGF therapies show that these treatment
are accompanied of numerous unexpected side effects
unrelated to the procedure used, including inflammation
and fibrosis [24], development of RPE tears [30] and
macular detachment [31]. In addition, other potential
undesired off-target effects should be considered with
chronic use of intravitreal anti-VEGF agents. Thus, the
long-term inhibition of VEGF could adversely affect the
health of neural retina, RPE and choriocapillaries, since
these tissues constitutively express VEGF and rely on it
for maintaining retinal health [32,33]. Accordingly,
twenty percent of people with age-related macular de-
generation (AMD) treated with anti-VEGF therapy have
been shown to lose vision over time [34,35]. Thesecaveats against the use of anti-VEGF therapy support
the search of new efficient and safe therapies for ocular
angiogenesis-related diseases.
Fibroblast growth factor (FGF) participates in CNV
[36-39] which is a biological process associated with
chronic CSC. The aim of the present interventional case
was to find out whether intravitreal dobesilate, a specific
FGF inhibitor [3] is a therapeutic option in the treat-
ment of subretinal or intraretinal fluid accumulation sec-
ondary to chronic CSC. As FGF is a necessary mediator
of VEGF activity, dobesilate also inhibits the last signal-
ing network, as it has been recently reported [4].
Case presentation
A 57-year-old Caucasian man presented at the Emer-
gency Service because of onset of sudden blurred vision.
He had suffered recurrent episodes of CSC for one year.
The patient had received three consecutive monthly
injections of Avastin with unsatisfactory results. Three
months after the end of Avastin treatment, the patient
was referred having had intense methamorphia in the
right eye for the previous last five days.
Methods
Ophthalmologic evaluations at baseline and 11 days after
treatment included fundoscopy, Snellen visual acuity
(VA) testing, fluorescein angiography and optical coher-
ence tomography (OCT) through the dilated pupila.
Central thickness was measured in OCT and defined as
the distance between the internal limiting membrane
and RPE, and included intraretinal fluid.
The eye was prepared in a standardized fashion, in
compliance with the Helsinki Declaration. The patient
received an intravitreal solution of dobesilate (150 μl) in
his right eye under strict sterile conditions, following the
International Guidelines for intravitreal injections [40].
Dobesilate was administered as a 12.5% solution of
diethylammonium 2,5-dihydroxybenzenesulfonate (etam-
sylate; Dicynone Sanofi-Aventis). The pH of the solution
was 3.2 at the opening of the phial and 5.2 after a 1:20 di-
lution in Milli-Q water. Mitogenesis experiments, carried
out as described by Fernández et al. [3], show that etam-
sylate inhibits FGF-driven mitogenesis with the same effi-
ciency as the potassium dobesilate salt employed in those
studies, which first demonstrated this inhibitory activity
(not shown).
After Ethical Committee approval from our Institu-
tion, informed consent was obtained from the patient
after explanation of the nature and possible conse-
quences of the study.
Results
At baseline, colour retinography appeared normal
(Figure 1A) and fluorescein angiography revealed a single
Figure 1 Colour retinography at baseline (A) Fluorescein angiography before dobesilate treatment (B) Spectral domain optical coherence
tomogram (OCT), showing fluid-filled spaces in the area temporal to the fovea that distorts the normal architectural arrangement of the
constituent cellular layer (C) The eye eleven days after receiving intravitreal injection of dobesilate, with marked resolution of intraretinal edema
(D) Horizontal arrows indicate the localization of the OCT scans on the corresponding color fundus photography and fluorescein angiogram.
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of CSC (Figure 1B). No diffuse degradation of the RPE
was seen on the fluorescent angiogram. The OCT image
depicted retinal cystoid abnormalities, and interstitial
and subretinal fluid accumulation (Figure 1C). After
dobesilate treatment, complete resolution of the intraret-
inal fluid was documented by OCT after eleven days
follow-up (Figure 1D), with a corresponding visual im-
provement. At that point VA also showed an important
improvement (0.4 at baseline vs. 0.8 after treatment), and
there was an increase of four lines from baseline. Com-
pared to baseline, retinal macular thickness (530 μm vs.
329 μm) and foveal retinal thickness (255 μm vs. 200 μm)
had also decreased significantly. Choroidal detail revealed
decreased vascular images, better seen in the area tem-
poral to the fovea. No ocular or systemic side effects
were observed. These effects were accompanied by focal
fluorescent leak disappearance after treatment (not
shown). The patient maintained this level of visual im-
provement during a month of follow-up.
Discussion
Calcium dobesilate is the active principle of Doxium a
drug used for more than 35 years. It has been orally
administered for the treatment of diabetic retinopathy
with a good safety profile [41]. Haritoglu et al. [42]have carried out a statistically sound study to assess
the real clinical benefits of oral calcium dobesilate
(Doxium) in the treatment of diabetic retinopathies.
The study concluded that the oral administration of
dobesilate did not show statistically significant clinical
benefits. The discrepancy between these last results
and those reported here may derive from the differ-
ences in the administration procedures. Oral adminis-
tration is probably not the best choice for dobesilate
to reach an adequate concentration at the vitreous.
Dobesilate has a very low product of solubility at the
acidic pH of the stomach, and further, readily oxidizes
at the duodenal pH. Accordingly, local delivery seems
a better choice in order to reach appropriate thera-
peutic concentrations of dobesilate in the case of
well-delimited targets, as is the case reported here.
Whether decreased leakage on fluorescein angiography
indicates regression of new immature vessels, or
whether it is simply a manifestation of the antiperme-
ability effect of the drug, remains an open question.
Recently, it has been reported that dobesilate abol-
ished VEGF-induced vascular hyperpermeability [4].
This activity of dobesilate may account for the restor-
ation of barrier malfunction in microvascular endo-
thelial cells by normalization of tight junction
proteins levels and organization [43].
Cuevas et al. European Journal of Medical Research 2012, 17:22 Page 4 of 5
http://www.eurjmedres.com/content/17/1/22The case we present suggests that dobesilate could be
an efficient therapeutic agent in conditions of intraret-
inal fluid accumulation secondary to chronic CSC. Intra-
vitreal dobesilate treatment led to significant reduction
of central retinal thickness and significant gain in VA,
and may improve the future management of CSC and
other related blindness diseases. Obviously, the actual
clinical value of dobesilate against CSC described here
needs to be further investigated in a prospective rando-
mized clinical trial with a longer follow-up. This study is
ongoing.
Conclusion
Intravitreal injection of dobesilate appears to lead to an
improvement of visual acuity and neurosensory detach-
ment, secondary to chronic serous chorioretinopathy, at
least in the short term. Neither ocular toxicity nor ad-
verse effects were observed. However, long-term studies
are required with an adequate number of patients.
Consent
Written informed consent was obtained from the patient
for publication of this manuscript and accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-chief on this journal.
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